ClinicalTrials.gg
CompletedNCT06554639Updated Oct 15, 2024

A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011)

A Phase 1 interventional study of MK-5684 and Prednisone in Prostatic Neoplasms, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2024, 2 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Prostatic Neoplasms by Merck & Co., Inc — 4 open to participants now, 6 under way, 3 of them phase 3. Prostatic Neoplasms · Merck & Co., Inc.

Enrollment
18th of 22
12 · median 93
Started
2024
with 2 others
Phase 1
6 of 22
none open now
Registered
19th of 22
by date

Among the 22 studies in Prostatic Neoplasms by Merck & Co., Inc, this one is the 18th largest by enrollment, is one of 3 that started in 2024, is one of 6 in phase 1, and was the 19th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

4 of the 22 studies in Prostatic Neoplasms by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Prostatic Neoplasms by Merck & Co., Inc, or all of them as a file.
02

Study summary

Researchers have designed a study medicine called MK-5684 as a new way to treat prostate cancer.

The purpose of this study is to learn what happens to MK-5684 in a person's body over time (a pharmacokinetic or PK study). Researchers will compare what happens to MK-5684 in the body when it is given with and without another medicine called diltiazem.

03

Conditions studied

  • Prostatic Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Continuous non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior to the first dosing based on participant self-reporting
  • (BMI) ≥18.0 and ≤32.0 kg/m\^2
  • Able to swallow multiple tablets

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • History or presence of any of the following:

    • Adrenal insufficiency
    • Hepatic or renal impairment
    • hypotension, cardiac arrhythmia, cardiac conduction abnormalities, or recurrent unexplained syncopal events
    • Second- or third-degree Atrioventricular (AV) heart block (except in participants with a functional artificial pacemaker)
    • Clinically significant sick sinus syndrome
    • Presence of any systemic fungal infection
    • Chronic infection
    • Glaucoma
    • Hypothyroidism
    • Stomach ulcer
    • Ocular herpes simplex
  • Has a first-degree relative with multiple unexplained syncopal events, unexplained cardiac arrest, or sudden cardiac death, or has a known family history of an inherited arrhythmia syndrome (including Brugada syndrome)
  • History of cancer ()
  • Unable to refrain from or anticipants the use of: Unable to refrain from or anticipates the use of: Any drugs, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to the first dosing
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    MK-5684 Period 1

    On Day 1 a single dose of MK-5684 will be administered under fasting conditions and a single dose of HRT (prednisone and fludrocortisone) will be administered under fed conditions approximately 4.5 hours after MK-5684 dosing.

    Drug: MK-5684 · Drug: Prednisone · Drug: Fludrocortisone acetate

  • Experimental
    MK-5684 Period 2

    There will be a washout of at least 5 days between MK-5684 dosing in Period 1 and the first diltiazem dosing in Period 2. In Period 2, diltiazem will be administered once daily (QD) for 6 consecutive days with a single dose of MK-5684 coadministered on Day 2 under fasting conditions. HRT (prednisone and fludrocortisone) will be administered under fed conditions QD on Days 2 through 5, approximately 4.5 hours after MK-5684 and/or diltiazem dosing.

    Drug: MK-5684 · Drug: Prednisone · Drug: Fludrocortisone acetate · Drug: Diltiazem hydrocholoride

Interventions

  • Administered via oral tablet per dosing regimen.

  • Administered at a dose of 2.5 mg or 5 mg dependent on HRT dosing regimen via oral tablets.

  • Administered at a dose of 0.05 mg per HRT dosing regimen via oral tablets.

  • DrugDiltiazem hydrocholoride

    Administered at a dose of 240 mg per dosing regimen via oral capsule (extended-release).

06

What researchers measure

Primary outcomes

  1. Area under the concentration versus time curve from 0 to infinity after single dosing (AUC0-inf) of MK-5684 in plasma

    AUC0-inf of MK-5684 in plasma will be determined.

    Time frame: Predose, and at designated timepoints up to 120 hours post-dose

  2. Area under the concentration versus time curve from 0 to last quantifiable sample (AUC0-last) of MK-5684 in plasma

    AUC0-last of MK-5684 in plasma will be determined.

    Time frame: Predose, and at designated timepoints up to 120 hours post-dose

  3. Area under the concentration versus time curve from 0 to Hour 24 (AUC0-24) of MK-5684 in plasma

    AUC0-24 of MK-5684 in plasma will be determined.

    Time frame: Predose, and at designated timepoints up to 24 hours post-dose

  4. Maximum concentration (Cmax) of MK-5684 in plasma

    Cmax of MK-5684 in plasma will be determined.

    Time frame: Predose, and at designated timepoints up to 120 hours post-dose

  5. Time to Maximum concentration (Tmax) of MK-5684 in plasma

    Tmax of MK-5684 in plasma will be determined.

    Time frame: Predose, and at designated timepoints up to 120 hours post-dose

  6. Apparent terminal half-life (t1/2) of MK-5684 in plasma

    t1/2 of MK-5684 in plasma will be determined.

    Time frame: Predose, and at designated timepoints up to 120 hours post-dose

  7. Apparent Clearance (CL/F) of MK-5684 in plasma

    CL/F of MK-5684 in plasma will be determined.

    Time frame: Predose, and at designated timepoints up to 120 hours post-dose

  8. Apparent volume of distribution during terminal phase (Vz/F) of MK-5684 in plasma

    Vz/F of MK-5684 in plasma will be determined.

    Time frame: Predose, and at designated timepoints up to 120 hours post-dose

Secondary outcomes

  1. Number of participants who experience one or more adverse events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 39 days

  2. Number of participants who discontinue study intervention due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 39 days

07

Study locations

1 site
  • Celerion ( Site 0001)
    Tempe, Arizona 85283, United States
08

References and documents

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Aug 2024, 0 months.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 0 months is below that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2024
First posted
Aug 15, 2024
StartActual
Jul 11, 2024
Primary completionActual
Aug 5, 2024
CompletionActual
Aug 29, 2024
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06554639
Responsible party
Sponsor
First posted
Aug 15, 2024
Start date
Jul 11, 2024
Primary completion
Aug 5, 2024
Completion
Aug 29, 2024
Last update
Oct 15, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Opevesostat

Start the discussion